Analytical Method Transfer to a CMO/CDMO: What Should Be Ready Before Execution?

An analytical method is not transferred merely because its SOP has been emailed to a contract laboratory or manufacturing partner.

In a pharmaceutical CMO/CDMO project, analytical transfer is a controlled knowledge-transfer and laboratory-readiness activity. The receiving laboratory must be able to execute the procedure for its intended purpose using suitable equipment, trained personnel, controlled documentation and scientifically justified criteria.

This matters because analytical procedures may support starting-material testing, in-process controls, finished-product release, stability studies, cleaning validation, process-validation samples or regulatory submissions. A weak transfer can therefore affect more than one laboratory result: it can undermine the interpretability and timing of the wider transfer plan.

WHO TRS 1044 Annex 4 states that relevant analytical procedures should be implemented at the receiving testing laboratory before it tests samples for process-validation studies. WHO recognizes several possible transfer approaches and states that the selected strategy should be risk-based and scientifically justified. ^[1]

ICH Q2(R2) treats transfer to another laboratory in the context of analytical-procedure lifecycle change. Depending on the circumstances, the work may include comparative analysis, partial or full revalidation, co-validation or a justified decision that no additional transfer experiments are needed. ICH Q14 provides the complementary science- and risk-based lifecycle framework. ^[2]

The following eight gates are a practical author-developed synthesis informed by WHO and ICH guidance. They are not an official WHO, ICH or FDA checklist and should be adapted to the method, product, laboratory and regulatory context. They do not replace a project-specific protocol, quality agreement, regulatory assessment or responsible-person approval.

Gate 1 — Define the intended use and exact transfer scope

The first question is not simply whether the receiving laboratory can run the SOP. The first question is what decision the resulting data must support. A procedure used for early development may require a different transfer approach from one intended for commercial release, stability testing, a regulatory commitment or process-validation support.

The controlled scope should identify, as applicable:

• The product, starting material, packaging component or residue to be tested
• Dosage form, strength and relevant sample matrix
• The intended use of the analytical result
• Target markets or regulatory programmes
• Method types included and explicitly excluded
• Current validation, verification and lifecycle status
• The activities assigned to the sending unit and receiving unit

ICH Q2(R2) defines the objective of validation as demonstrating that an analytical procedure is fit for its intended purpose. ICH Q14 likewise links analytical procedure development and lifecycle control to intended use and performance. ^[2]

A vague request such as ‘transfer the HPLC method’ does not say whether the receiving laboratory will perform assay, related substances, stability testing, release testing, verification, investigation support or some combination. Gate 1 should end with a scope statement understood by technical, quality and project owners.

Gate 2 — Establish ownership and quality responsibilities

Analytical transfer is a cross-organizational activity. Responsibilities should be written before samples arrive or testing begins.

WHO describes distinct sending-unit and receiving-unit responsibilities. The sending unit normally provides method knowledge, approved procedures, relevant validation and robustness information, method-specific training, equipment details where needed, technical support and review of the transfer report. The receiving unit reviews the method, agrees acceptance criteria before execution, confirms laboratory readiness, executes the protocol and generates or obtains approval of the report. ^[1]

For outsourced work, FDA’s quality-agreement guidance describes how parties can define and document their respective manufacturing activities and quality responsibilities. The technical transfer protocol and the quality agreement are connected but different: the protocol governs the planned transfer exercise; the quality agreement governs the longer-term responsibility interface if the relationship proceeds. ^[5]

• Protocol ownership, review and approval
• Training, samples, reference standards and technical support
• Equipment, software and documentation readiness
• Execution, second-person review and data review
• Deviation, atypical result and investigation handling
• Report preparation, approval, change control and record access
• Communication, escalation and lifecycle review

Gate 3 — Complete the knowledge-package and gap assessment

A controlled method document is necessary, but it rarely contains every detail that determines reproducible execution. Before selecting the experiment, the parties should identify what knowledge is available, what remains uncertain and what confidential material may be needed later under controlled access.

The following is a risk-based project checklist, not a universal list mandated item by item by WHO or ICH. Depending on the procedure and intended use, relevant materials may include:

• The current approved analytical procedure and its revision history
• Development, validation and prior transfer reports
• Known sensitivities, robustness knowledge and difficult execution steps
• Sample preparation, hold-time and solution-stability information
• Reference and impurity standards, reagents, columns and consumables
• Instrument configuration, software, calculations and integration conventions
• Representative outputs, system-suitability requirements and known failure modes
• Training and troubleshooting knowledge

WHO expects relevant analytical procedure development and validation documentation to be made available by the sending unit when required. ICH Q14 emphasizes analytical understanding and knowledge management across the lifecycle. ^[1]

The purpose is not to send every internal document. It is to decide whether the receiving unit has enough controlled knowledge to design and interpret the transfer and to create a gap register with owners and closure criteria.

Gate 4 — Select a risk-based transfer strategy

There is no single transfer design suitable for every analytical procedure. WHO identifies confirmation testing, comparability testing between sending and receiving units, co-validation between laboratories and paper-based knowledge transfer as possible approaches. The strategy chosen should be risk-based and scientifically justified. ^[1]

ICH Q2(R2) states that transfer to a different laboratory may involve partial or full revalidation and/or comparative analysis of representative samples. It also allows a justified decision not to perform additional transfer experiments and recognizes that co-validation using data from multiple sites may satisfy transfer requirements for participating sites. ^[2]

The strategy should consider intended use and regulatory importance, procedure complexity and robustness, matrix and product characteristics, differences in equipment or software, receiving-laboratory experience, available samples and standards, existing validation evidence and the history of method performance or change.

As a project-risk principle, paper-based knowledge transfer should not be selected solely for schedule convenience. Where it is used, the documented rationale should explain why existing knowledge and evidence make additional experimental work unnecessary. Conversely, full revalidation should not be imposed automatically when a focused comparative or partial-revalidation strategy is scientifically sufficient.

Gate 5 — Approve the protocol and acceptance criteria before execution

Transfer testing should begin under an approved protocol or transfer plan. WHO states that the plan should define the objective, scope, sending-unit and receiving-unit responsibilities, materials and methods, experimental design, acceptance criteria, documentation, deviation handling and test samples. ^[1]

WHO specifically calls for an analytical procedure transfer protocol or test-transfer plan. Where the selected transfer strategy includes validation or revalidation work, ICH Q2(R2) additionally states that the validation study should be governed by a protocol defining the intended purpose, performance characteristics and associated criteria. ^[2]

• Objective, scope and scientific rationale
• Methods and controlled documents being transferred
• Samples, standards, reagents and required materials
• Equipment, platform and participating laboratory requirements
• Experimental design, calculations and data review
• Predefined acceptance criteria
• Deviation, invalid-test and change handling
• Report content and approval requirements

The cited WHO and ICH sections do not prescribe one universal number of analysts, samples, runs or batches for every transfer. WHO requires the number of analysts, experimental parameters and acceptance criteria to be defined and justified; the actual design remains project-specific. ^[1]

Gate 6 — Confirm receiving-laboratory readiness

A technically sound protocol can still fail if the receiving laboratory is not ready. WHO assigns the receiving unit responsibility for ensuring that necessary equipment is available and qualified, adequately trained and experienced personnel are in place, and the documentation system can record sample receipt, testing, results and status. ^[1]

• Required equipment is available, qualified and suitably configured
• Software, calculations and data-review workflows are controlled
• Standards, samples, reagents, columns and consumables are available and suitable
• The current procedure and related documents are under document control
• Method-specific training is complete and documented
• Review, approval, sample traceability and status designation are defined
• The laboratory can execute the protocol within the agreed project window

Owning the same instrument model is not enough. Practical differences that may need assessment include detector configuration, software processing, column availability, environmental conditions, analyst experience and documentation practice. Material readiness gaps should be closed or explicitly controlled before execution.

Gate 7 — Execute under control and investigate material departures

Execution should follow the approved protocol and generate a complete, reviewable record. The governance plan should address protocol deviations, atypical or unexpected results, invalid runs, acceptance-criterion failures, equipment interruptions, changes made during execution and technical questions requiring sending-unit support.

If predefined criteria are not met, the outcome should be handled through the protocol’s deviation and investigation process. Any additional testing or protocol change should be scientifically justified, approved and documented; an unplanned passing result should not by itself be treated as evidence of successful transfer. The assessment should consider whether the issue relates to method knowledge, equipment, materials, training, execution or study design.

WHO expects the protocol to define deviation handling and requires deviations and changes to be documented and investigated where appropriate. FDA’s quality-agreement guidance supports clear assignment of quality activities and communication in contract arrangements. ^[1]

Gate 8 — Approve the report and place the procedure under lifecycle control

Testing completion is not transfer closure. The final report should state what was executed, the results obtained, deviations and investigations, comparison with predefined criteria, remaining limitations or actions, the conclusion and the approved status for the defined intended use.

WHO expects a technology-transfer report based on project data and information, with an assessment, conclusion and authorization by the appropriate responsible person or persons. It should state whether the transfer was completed and evaluate deviations and changes before close-out. ^[1]

ICH Q2(R2) treats laboratory transfer as part of the analytical-procedure lifecycle, and ICH Q14 applies risk-based bridging and change management to later changes. Future changes to equipment, software, materials, parameters, product knowledge or intended use may require another risk assessment and further verification or validation. ^[3]

The report should end with a bounded decision: ready for the defined use; conditionally ready subject to named actions; on hold pending gap closure; or not accepted under the current design. It should not imply a broader result than the protocol evaluated.

A practical readiness decision

A project is more defensible to schedule when the intended use and scope are unambiguous, responsibilities are documented, the knowledge package has been reviewed, material gaps have owners, the strategy is scientifically justified, protocol and criteria are approved, the receiving laboratory is ready, and deviation, reporting and change-control routes are defined. One practical project-status model—not terminology prescribed by WHO or ICH—is shown below.

The work should remain on hold when missing information or readiness gaps could make the experiment uninterpretable, invalidate the comparison or create uncontrolled quality or regulatory risk.

What can be shared in a non-confidential first inquiry?

For this website’s conservative first-contact workflow, a preliminary discussion does not require proprietary analytical details. Useful non-confidential information can include dosage form and general product category, target market, project and lifecycle stage, analytical method types, current validation or verification status, proposed transfer scope, desired timing, and whether comparative testing, verification, validation or routine testing is being considered.

Conclusion

Analytical method transfer is a decision system, not a document-delivery event. A defensible transfer connects intended use, scientific knowledge, laboratory readiness, predefined criteria, controlled execution, documented closure and lifecycle management.

The exact design remains product-, method-, laboratory- and market-specific. Completion of an analytical transfer does not by itself demonstrate manufacturing-site readiness, product registration, regulatory approval, batch-release suitability, project acceptance, available capacity, pricing, timeline or commercial success.

Frequently asked questions

This article is a source-based industry perspective for general business discussion. It is not legal, regulatory, quality, validation or medical advice and is not a conclusion about any company, facility, method or project. Responsible parties and applicable authorities must confirm project-specific requirements.